Beatriz Merino1, Cristina M Fernández-Díaz2, Cristina Parrado-Fernández3, Carlos M González-Casimiro4, Tamara Postigo-Casado5, Carmen D Lobatón6, Malcolm A Leissring7, Irene Cózar-Castellano8, Germán Perdomo9. 1. Instituto de Biología y Genética Molecular (University of Valladolid-CSIC), Valladolid, Spain. 2. Instituto de Biología y Genética Molecular (University of Valladolid-CSIC), Valladolid, Spain. Electronic address: cristinamaria.fernandez@imdea.org. 3. Instituto de Biología y Genética Molecular (University of Valladolid-CSIC), Valladolid, Spain; AlzeCure Pharma AB, Huddinge, Sweden. 4. Instituto de Biología y Genética Molecular (University of Valladolid-CSIC), Valladolid, Spain. Electronic address: carlosmanuel.gonzalez.casimiro@uva.es. 5. Instituto de Biología y Genética Molecular (University of Valladolid-CSIC), Valladolid, Spain. Electronic address: tamara.postigo@uva.es. 6. Instituto de Biología y Genética Molecular (University of Valladolid-CSIC), Valladolid, Spain. Electronic address: clobaton@ibgm.uva.es. 7. Institute for Memory Impairments and Neurological Disorders, University of California, Irvine (UCI MIND), Irvine, CA, USA. Electronic address: m.leissring@uci.edu. 8. Instituto de Biología y Genética Molecular (University of Valladolid-CSIC), Valladolid, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain. Electronic address: irene.cozar@uva.es. 9. Instituto de Biología y Genética Molecular (University of Valladolid-CSIC), Valladolid, Spain; Departamento de Ciencias de la Salud, Universidad de Burgos, Burgos, Spain. Electronic address: g.perdomo@csic.es.
Abstract
The insulin-degrading enzyme (IDE) is a metalloendopeptidase with a high affinity for insulin. Human genetic polymorphisms in Ide have been linked to increased risk for T2DM. In mice, hepatic Ide ablation causes glucose intolerance and insulin resistance when mice are fed a regular diet. OBJECTIVE: These studies were undertaken to further investigate its regulatory role in glucose homeostasis and insulin sensitivity in diet-induced obesity. METHODS: To this end, we have compared the metabolic effects of loss versus gain of IDE function in mice fed a high-fat diet (HFD). RESULTS: We demonstrate that loss of IDE function in liver (L-IDE-KO mouse) exacerbates hyperinsulinemia and insulin resistance without changes in insulin clearance but in parallel to an increase in pancreatic β-cell function. Insulin resistance was associated with increased FoxO1 activation and a ~2-fold increase of GLUT2 protein levels in the liver of HFD-fed mice in response to an intraperitoneal injection of insulin. Conversely, gain of IDE function (adenoviral delivery) improves glucose tolerance and insulin sensitivity, in parallel to a reciprocal ~2-fold reduction in hepatic GLUT2 protein levels. Furthermore, in response to insulin, IDE co-immunoprecipitates with the insulin receptor in liver lysates of mice with adenoviral-mediated liver overexpression of IDE. CONCLUSIONS: We conclude that IDE regulates hepatic insulin action and whole-body glucose metabolism in diet-induced obesity via insulin receptor levels.
The insulin-degrading enzyme (IDE) is a metalloendopeptidase with a high affinity for insulin. Human genetic polymorphisms in Ide have been linked to increased risk for T2DM. In mice, hepatic Ide ablation causes glucose intolerance and insulin resistance when mice are fed a regular diet. OBJECTIVE: These studies were undertaken to further investigate its regulatory role in glucose homeostasis and insulin sensitivity in diet-induced obesity. METHODS: To this end, we have compared the metabolic effects of loss versus gain of IDE function in mice fed a high-fat diet (HFD). RESULTS: We demonstrate that loss of IDE function in liver (L-IDE-KO mouse) exacerbates hyperinsulinemia and insulin resistance without changes in insulin clearance but in parallel to an increase in pancreatic β-cell function. Insulin resistance was associated with increased FoxO1 activation and a ~2-fold increase of GLUT2 protein levels in the liver of HFD-fed mice in response to an intraperitoneal injection of insulin. Conversely, gain of IDE function (adenoviral delivery) improves glucose tolerance and insulin sensitivity, in parallel to a reciprocal ~2-fold reduction in hepatic GLUT2 protein levels. Furthermore, in response to insulin, IDE co-immunoprecipitates with the insulin receptor in liver lysates of mice with adenoviral-mediated liver overexpression of IDE. CONCLUSIONS: We conclude that IDE regulates hepatic insulin action and whole-body glucose metabolism in diet-induced obesity via insulin receptor levels.
Authors: Beatriz Merino; Elena Casanueva-Álvarez; Iván Quesada; Carlos M González-Casimiro; Cristina M Fernández-Díaz; Tamara Postigo-Casado; Malcolm A Leissring; Klaus H Kaestner; Germán Perdomo; Irene Cózar-Castellano Journal: Diabetologia Date: 2022-06-02 Impact factor: 10.460
Authors: Malcolm A Leissring; Carlos M González-Casimiro; Beatriz Merino; Caitlin N Suire; Germán Perdomo Journal: Int J Mol Sci Date: 2021-02-24 Impact factor: 5.923
Authors: Carlos M González-Casimiro; Beatriz Merino; Elena Casanueva-Álvarez; Tamara Postigo-Casado; Patricia Cámara-Torres; Cristina M Fernández-Díaz; Malcolm A Leissring; Irene Cózar-Castellano; Germán Perdomo Journal: Biomedicines Date: 2021-01-17
Authors: Meera Ladwa; Oluwatoyosi Bello; Olah Hakim; Maria Linda Boselli; Fariba Shojaee-Moradie; A Margot Umpleby; Janet Peacock; Stephanie A Amiel; Riccardo C Bonadonna; Louise M Goff Journal: Acta Diabetol Date: 2021-10-18 Impact factor: 4.280
Authors: Carine Marmentini; Gabriela M Soares; Gabriela A Bronczek; Silvano Piovan; Cecília E Mareze-Costa; Everardo M Carneiro; Antonio C Boschero; Mirian A Kurauti Journal: Front Endocrinol (Lausanne) Date: 2021-05-12 Impact factor: 5.555